THURSDAY, SEPTEMBER 29, 2016

Study shows advances for effective, long-lasting flu vaccine

Study shows advances for effective, long-lasting flu vaccine. | Courtesy of medicalexpo.com

A study recently conducted by scientists from the Janssen Pharmaceutical Companies of Johnson & Johnson (Janssen) as well as The Scripps Research Institute (TSRI) shows a new way to produce antibodies to battle against a variety of influenza subtypes.

This further advances research for a new, more effective, long-lasting influenza vaccine. The collaboration demonstrated that a vaccine candidate induced strong, broadly neutralizing antibodies within animal models.

This discovery could end the need for yearly seasonal flu shots.

This single study is just one part of the long-term collaboration that TSRI has with Janssen Prevention Center, which is based in Leiden, the Netherlands. The goal of the partnerships is to strengthen the research against infectious diseases.

“This study shows that we’re moving in the right direction for a universal flu vaccine,” Ian Wilson, Hansen professor of structural biology and chair of the Department of Integrative Structural and Computational Biology at TSRI, said.

Each year, seasonal flu results in over 200,000 hospitalizations as well as 36,000 deaths within the U.S. Health professionals maintain that influenza vaccinations are the best way to protect people from contracting seasonal flus.

“While there is more work to be done, the ultimate goal, of course, would be to create a life-long vaccine,” Wilson said.

Further details are available online in Science journal.

Organizations in this story

Scripps Health 130 Cedar Rd Vista, CA 92083

Get notified the next time we write about Scripps Health!